Skip to content

Examining the Effects of a Remote Pulmonary Rehabilitation Program in the Severe Asthma Population.

STAPLE (Severe asThmA PuLmonary rEhab): Examining the Effects of a Remote Pulmonary Rehabilitation Program in the Severe Asthma Population.

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06150300
Acronym
STAPLE
Enrollment
34
Registered
2023-11-29
Start date
2024-01-01
Completion date
2026-12-31
Last updated
2023-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

This is a randomized control trial evaluating the effect of a novel mobile application-delivered pulmonary rehabilitation program in adult severe asthma patients. The intervention will include eight weeks of exercise videos that progress in difficulty, as well as asthma-specific educational content. The primary outcome measure is change in functional exercise capacity as measured by six-minute walk distance. Secondary outcome measures will include evaluation of overall feasibility, and change in CPET parameters such as VO2max. Change in asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ) and PRAISE self-efficacy score will also be evaluated.

Interventions

BEHAVIORALPulmonary rehab program

Exercise videos, breathing exercises, and educational messages delivered virtually

BEHAVIORALPlacebo

Breathing exercises and educational messages

Sponsors

University of Saskatchewan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 years and older with a diagnosis of asthma by a respirologist. They must have severe disease defined by GINA severity classification. Participants must have access to a smartphone or internet browser to allow access to study content.

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
CPETAfter 8 weeks of interventionVO2max

Contacts

Primary ContactBrianne Philipenko, MD
bsp943@mail.usask.ca306-956-3444

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026